Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AMG 330 |
Synonyms | |
Therapy Description |
AMG 330 (Eluvixtamab) is a bispecific antibody that targets both CD33 and CD3, resulting in cytotoxic activity against CD33-positive cells (PMID: 24674885, PMID: 30396365). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG 330 | AMG330|AMG-330|Eluvixtamab | CD3 Antibody 99 CD33 Antibody 13 | AMG 330 (Eluvixtamab) is a bispecific antibody that targets both CD33 and CD3, resulting in cytotoxic activity against CD33-positive cells (PMID: 24674885, PMID: 30396365). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02520427 | Phase I | AMG 330 | A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Terminated | USA | NLD | DEU | CAN | 0 |